Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to the Usual Radiation Treatment for Newly Diagnosed Early Stage High Intermediate Risk Endometrial Cancer identifier:
NCT04214067 (

Study Contact Information:

Principal Investigator: Floor Backes    

For additional information: Use the contacts listed per each study location. 

About the Study

The purpose of this study is to determine whether the addition of the immunotherapy agent, pembrolizumab (Keytruda) to radiation therapy is more effective than radiation therapy alone in reducing the risk of cancer recurrence in patients with newly diagnosed stage I-II endometrial cancer that is MSI-High. NOTE: This study is no longer enrolling. 


This Study is Open To:

This study is no longer enrolling.

This Study is Not Open To:


FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.